- PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3,000,000 from Chugai
- PharmaMar progresses in the clinical development of Zepsyre® in Japanwhile its ATLANTIS global registration trial in small-cell lung cancer continues
- ATLANTIS trial has successfully passed two safety analyses by the IDMC after inclusion of 150 and 500 patients, respectively . ...